Journals / Journal of Health Sciences and Medicine / 2026 / Volume: 9 Issue: 2

Comparison of the colorimetric microdilution-based commercial MICRONAUT-AM test with the conventional broth microdilution test in assessing antifungal susceptibility of multidrug-resistant Candidozyma (Candida) auris

Deniz Turan(Sağlık Bilimleri Üniversitesi, Haydarpaşa Numune Eğitim ve Araştırma Hastanesi, Tıbbi Mikrobiyoloji)0000-0001-7943-7536
Sebahat Aksaray(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, HAMİDİYE TIP FAKÜLTESİ, TEMEL TIP BİLİMLERİ BÖLÜMÜ, TIBBİ MİKROBİYOLOJİ ANABİLİM DALI, KLİNİK MİKROBİYOLOJİ BİLİM DALI)0000-0002-0552-1337
Pages
—
Publication Date
2026-03-12
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Confirmation of these results through comparative studies involving different commercial kits is necessary to determine whether similar findings can be observed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aims: Candidozyma (Candida) auris is a pathogen that causes invasive infections and develops multidrug resistance.
📊
Key Findings & Data:Methods: The material of this comparative study consisted of 116 C. auris strains isolated between February 2024 and April 2024.
💡
Conclusion & Impact:Confirmation of these results through comparative studies involving different commercial kits is necessary to determine whether similar findings can be observed.
🔬Design:Experimental Field Trial
📍Scope:2024 Verileri
⚙️Variables:Candidozyma (Candida) auris · antifungal susceptibility · MICRONAUT-AM

Abstract

Aims: Candidozyma (Candida) auris is a pathogen that causes invasive infections and develops multidrug resistance. Antifungal susceptibility testing is vital for therapeutic management. In this context, this study was conducted to compare the efficacies of the commercial MICRONAUT-AM test (MN) and the conventional broth microdilution test (BMD) in assessing antifungal susceptibility of C. auris isolates. Methods: The material of this comparative study consisted of 116 C. auris strains isolated between February 2024 and April 2024. The efficacies of MN and BMD in assessing the susceptibility of C. auris isolates to antifungal agents, including fluconazole, amphotericin B, micafungin, and anidulafungin, were compared. To this end, the agreement and essential agreement between the two tests and minor, major, and very major error rates were calculated. Results: The agreement between the two tests was found to be high (98.3%) in assessing the susceptibility of C. auris isolates to micafungin and anidulafungin agents but low in assessing their susceptibility to fluconazole and amphotericin B agents. C. auris isolates were found to be 66.4% resistant to fluconazole with BMD and 94.8% resistant with MN, while they were found to be 44% resistant to amphotericin B with BMD and not resistant with MN. Compared to the reference method BMD, the MN detected the resistance of C. auris isolates against micafungin and anidulafungin agents with high accuracy but could not accurately detect their resistance against fluconazole and amphotericin B agents. Conclusion: Our findings suggest that the commercial test kit evaluated in this study may require optimization with respect to the antifungal agents it includes. Confirmation of these results through comparative studies involving different commercial kits is necessary to determine whether similar findings can be observed.

🔖

Cite This Article

Turan, D., Aksaray, S. (2026). Comparison of the colorimetric microdilution-based commercial MICRONAUT-AM test with the conventional broth microdilution test in assessing antifungal susceptibility of multidrug-resistant Candidozyma (Candida) auris. Journal of Health Sciences and Medicine, Volume: 9 Issue: 2. https://doi.org/10.32322/jhsm.1842805

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (22)

  1. Arastehfar A, Gabaldon T, Garcia-Rubio R et al. Drug-resistant fungi: an emerging challenge threatening our limited antifungal armamentarium. Antibiotics. 2020;9(12):877. doi:10.3390/antibiotics9120877
  2. Beardsley J, Halliday CL, Chen SCA, Sorrell TC. Responding to the emergence of antifungal drug resistance: perspectives from the bench and the bedside. Future Microbiol. 2018;13(10):1175-1191. doi:10.2217/fmb-2018-0059
  3. Silva I, Miranda IM, Costa-de-Oliveira S. Potential environmental reservoirs of Candida auris: a systematic review. J Fungi. 2024;10(5):336. doi:10.3390/jof10050336
  4. Otto WR, Arendrup MC, Fisher BT. A practical guide to antifungal susceptibility testing. Pediatr Infect Dis J. 2023;12(4):214-221. doi:10. 1093/jpids/piad014
  5. Philips S, Van Hoecke F, Laere ED, et al. Comparison of two commercial colorimetric broth microdilution tests for Candida susceptibility testing: Sensititre YeastOne versus MICRONAUT-AM. J Fungi. 2021;7(5):356. doi:10.3390/jof7050356
  6. Trovato L, Calvo M, Scalia G, Oliveri S. A comparative prospective study in evaluating Candida spp. in vitro susceptibility through Micronaut-AM and Sensititre Yeast-One. Microbiol Res. 2023;14:1077-1088. doi:10.3390/microbiolres14030072
  7. Pellaton N, Sanglard D, Lamoth F, Coste AT. How yeast antifungal resistance gene analysis is essential to validate antifungal susceptibility testing systems. Front Cell Infect Microbiol. 2022;12:859439. doi:10.3389/fcimb.2022.859439
  8. Szabo NG, Joste V, Houze S, Dannaoui E, Bonnal C. Comparison of the Micronaut-AM system and the EUCAST broth microdilution reference method for MIC determination of four antifungals against Aspergillus fumigatus. J Fungi. 2023;9(7):721. doi:10.3390/jof9070721
  9. Gorzynska A, Kondracka K, Korzeniowska-Kowal A, Nawrot U. Antifungal susceptibility of Saccharomyces cerevisiae isolated from clinical specimens. Pathogens. 2024;13(3):248. doi:10.3390/pathogens 13030248
  10. Arendrup MC, Prakash A, Meletiadis J, Sharma C, Chowdhary A. Comparison of EUCAST and CLSI reference microdilution MICs of eight antifungal compounds for Candida auris and associated tentative epidemiological cutoff values. Antimicrob Agents Chemother. 2017;61(6): e00485-17. doi:10.1128/aac.00485-17
  11. Cilo BD, Topaç T, Ağca H, Sağlam S, Efe K, Ener B. Comparison of Clinical Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution methods for determining the susceptibilities of Candida isolates. Mikrobiyol Bul. 2018;52(1):35-48. doi:10.5578/mb.63991
  12. https://www.cdc.gov/fungal/candida-auris/c-auris-antifungal.html
  13. Gülmez D. Candida auris: On yılda dünyaya yayılmayı başaran fungal patojen. Flora. 2019;24(4):263-271. doi:10.5578/flora.69056
  14. Corcione S, Montrucchio G, Shbaklo N, et al. First cases of Candida auris in a referral intensive care unit in piedmont region, Italy. Microorganisms. 2022;10:1521. doi:10.3390/microorganisms10081521
  15. Stanciu AM, Florea D, Surleac M, et al. First report of Candida auris in Romania: clinical and molecular aspects. Antimicrob Resist Infect Control. 2023;12(1):91. Published 2023 Sep 7. doi:10.1186/s13756-023-01297-x
  16. Sticchi C, Raso R, Ferrara L, et al. Increasing number of cases due to Candida auris in North Italy, July 2019-December 2022. J Clin Med. 2023;12(5):1912. doi:10.3390/jcm12051912
  17. Asadzadeh M, Mokaddas E, Ahmad S, et al. Molecular characterisation of Candida auris isolates from immunocompromised patients in a tertiary-care hospital in Kuwait reveals a novel mutation in FKS1 conferring reduced susceptibility to echinocandins. Mycoses. 2022;65: 331-343. doi:10.1111/myc.13419
  18. Mantzana P, Protonotariou E, Meletis G, Tychala A, Skoura L. The Micronaut–AM antifungal susceptibility testing method does not overestimate amphotericin B resistance in Candida auris. Microbiol Spectr. 2024;12(5):1-2. doi:10.1128/spectrum.00490-24
  19. Siopi M, Peroukidou I, Beredaki MI, et al. Overestimation of amphotericin B resistance in Candida auris with Sensititre YeastOne antifungal susceptibility testing: a need for adjustment for correct ınterpretation. Microbiol Spect. 2023;11(3):10.1128. doi:10.1128/spectrum.04431-22
  20. Koehling HL, Willinger B, Buer, J, Rath PM, Steinmann J. Comparative evaluation of a new commercial colorimetric microdilution assay (SensiQuattro Candida EU) with MIC test strip and EUCAST broth microdilution methods for susceptibility testing of invasive Candida isolates. J Clin Microbiol. 2015;53:255-261. doi:10.1128/jcm.02830-14
  21. Belik F, Deckers C, Khourssaji M, Huang TD, Denis O, Montesinos I. Comparative assessment of Sensititre YeastOne and Micronaut-AM EUCAST for antifungal susceptibility testing in candidaemia isolates. J Med Mycol. 2024;34:101465. doi:10.1016/j.mycmed.2024.101465
  22. Stanciu AM, Florea D, Surleac M, et al. First report of Candida auris in Romania: clinical and molecular aspects. Antimicrob Resist Infect Control. 2023;12(1):91. Published 2023 Sep 7. doi:10.1186/s13756-023-01297-x